Kezar Life Sciences

Please note: The information displayed on this page might be outdated.
Kezar Life Sciences: Clinical stage biotechnology company pioneering first-in-class, small molecule therapies designed to inhibit multiple disease-driving cellular pathways by targeting key intracellular proteins. The Company is advancing two differentiated therapeutic approaches: Selective Immunoproteasome Inhibition, for the treatment of autoimmune diseases through immune modulation versus direct immunosuppression; and Protein Secretion Inhibition, halting the secretion of target proteins that contribute to a range of cancers and autoimmune diseases. Lead candidate, zetomipzomib (KZR-616), a selective immunoproteasome inhibitor, is being evaluated in Phase 2 clinical trials for lupus nephritis and autoimmune hepatitis, and KZR-261, a first-in-class inhibitor of the Sec61 translocon developed using the Company’s novel discovery Protein Secretion Inhibition Platform, is undergoing a Phase 1 clinical trial for the treatment of advanced/metastatic solid tumors.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
US - Pacific
Clinical Stage
Phase l or ll
Disease Space
Autoimmune, Oncology
Industry
Biotechnology
Listing
Public, USA
Market Cap
<100MM
Therapeutic Modalities
Small Molecule
Website:
Profiles:
Address:
4000 Shoreline Court
Suite 300
South San Francisco, CA 94080
United States

Company Participants at Solebury 1x1 Management Access Event 2023

  • Christopher Kirk, PRESIDENT & CHIEF SCIENTIFIC OFFICER, CO-FOUNDER
  • John Fowler, CEO, Co-Founder
  • Marc L. Belsky, Chief Financial Officer
  • Nick Mordwinkin , PhD, Chief Business Officer
  • Noreen Henig, MD, CMO

Top 10 Holders of Kezar Life Sciences Inc

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Suvretta Capital Management LLC 9.90 7,167,591 8.53 13F 6/30/23
Avidity Partners Management LP 8.40 6,080,000 7.24 13F 6/30/23
OrbiMed Advisors LLC 7.54 5,463,000 6.50 13F 6/30/23
Prosight Management LP 6.42 4,651,920 5.54 13F 6/30/23
Millennium Management LLC 5.17 3,741,109 4.45 13F 6/30/23
Vanguard Group, Inc. (Subfiler) 4.12 2,982,519 3.55 13F 6/30/23
BlackRock Fund Advisors 4.07 2,949,364 3.51 13F 6/30/23
Sphera Funds Management Ltd. 2.75 1,988,228 2.37 13F 6/30/23
OrbiMed Advisors Private Equity 2.65 1,927,000 2.29 Funds 8/31/23
Granahan Investment Management, LLC 2.62 1,899,019 2.26 13F 6/30/23
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2023 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.